NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 300
- Changed in 7 days
- 7
- Latest record
- Jurisdiction
- International / multiple
Records
300 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348Conditions: Healthy; Obesity; Overweight. Interventions: Formulation A; Formulation B6 | Active, not recruiting | Phase 1 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07407348 (opens in a new tab)Primary source | System checked NPHLA updated |
| Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsNCT07935200Conditions: Bioequivalence; Pharmacokinetics. Interventions: Semaglutide (UI112); Semaglutide (UIC202611) | Not yet recruiting | Phase 1 | Korea United Pharm. Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07935200 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase I Study to Evaluate the Food Effect on Ecnoglutide TabletNCT07936058Conditions: Food Effect in Healthy Volunteers; Weight Management. Interventions: Dose 1; Dose 2 | Not yet recruiting | Phase 1 | Hangzhou Sciwind Biosciences Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07936058 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With OverweightNCT07936838Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Interventions: Lembas Edge™; Placebo | Not yet recruiting | Not applicable | Lembas | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07936838 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of BGM0504 in Participants With Type 2 DiabetesNCT06716216Changed in the last 7 days Status changed from “Active, not recruiting” to “Completed” · Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: Drug: 5 mg BGM0504 Administered SC; Drug:10 mg BGM0504 Administered SC; Drug: Semaglutide Administered SC | Completed | Phase 3 | BrightGene Bio-Medical Technology Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06716216 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Conditions: Type 2 Diabetes. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06297603 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMBITION 3: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothNCT07931573Conditions: Type 2 Diabetes. Interventions: Zenagamtide; Semaglutide; Placebo | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931573 (opens in a new tab)Primary source | System checked NPHLA updated |
| AMBITION4: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothNCT07931599Conditions: Diabetes Mellitus, Type 2. Interventions: Zenagamtide; Semaglutide; Placebo zenagamtide; Placebo semaglutide | Not yet recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931599 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary ComplicationsNCT07932119Conditions: GLP-1 Receptor Agonist Treatment. Interventions: GLP-1 Receptor Agonists; GLP-1 Receptor Agonists | Completed | Phase not stated | University of Virginia | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07932119 (opens in a new tab)Primary source | System checked NPHLA updated |
| SURMOUNT-1: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)NCT07481747Conditions: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities. Interventions: Tirzepatide; Placebo; Reduced-calorie diet | Recruiting | Phase 3 | Hudson Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07481747 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Retrospective Study to Assess Patient-Reported Treatment Experience With Over-the-Counter Analgesic ProductsNCT07931859Conditions: Pain. Interventions: Paracetamol | Not yet recruiting | Phase not stated | HALEON | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931859 (opens in a new tab)Primary source | System checked NPHLA updated |
| PRESERVE GLP-1: Lifestyle Strategies to Preserve Muscle and Reduce Cardiovascular Risk in Adults With Obesity Using GLP-1 Receptor AgonistsNCT07933393Conditions: Obesity & Overweight. Interventions: GLP-1 Lifestyle Management Program; Enhanced Usual Care Health Education | Not yet recruiting | Not applicable | University of Florida | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07933393 (opens in a new tab)Primary source | System checked NPHLA updated |
| COURAGE: A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass PreservationNCT06299098Conditions: Obesity. Interventions: Trevogrumab-Part A; Trevogrumab-Part B and Part C; Garetosmab; Semaglutide; Matching Placebo-Part A; Matching Placebo-T… | Completed | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06299098 (opens in a new tab)Primary source | System checked NPHLA updated |
| Changes in Body Composition and Muscle Composition After GLP-1 Receptor Agonist Therapy in Patients With ObesityNCT07931560Conditions: Obesity & Overweight | Not yet recruiting | Phase not stated | Ulsan University Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931560 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic ControlNCT07711288Conditions: Postprandial Glycemic Control; Prediabetic Overweight and Obese Adults. Interventions: Low dose alpha-galactosidase-derived peptide; Medium dose alpha-galactosidase-derived peptide; High dose alpha-galactos… | Recruiting | Not applicable | Lembas | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07711288 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or OverweightNCT07932925Conditions: Urinary Incontinence, Stress; Overweight and/or Obesity. Interventions: Berobenatide; Placebo | Not yet recruiting | Phase 3 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07932925 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284Conditions: Obesity. Interventions: Survodutide; Semaglutide | Active, not recruiting | Phase 1 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06745284 (opens in a new tab)Primary source | System checked NPHLA updated |
| Rutazyme Lemon Fermented Product Capsules for Metabolic Function in Adults With ObesityNCT07540949Conditions: Obesity; Metabolic Syndrome. Interventions: Rutazyme® Lemon Fermented Product Capsule; Placebo Capsule (Maltodextrin; GLUCIDEX®12) | Completed | Not applicable | National Taiwan Sport University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07540949 (opens in a new tab)Primary source | System checked NPHLA updated |
| PoLiFat: Medium-term Effects of a Polyphenol-rich Beverage Based on Red Grape Pomace Extract on Non-alcoholic Fatty Liver Disease, Cardiometabolic Risk Profile and Gut Microbiota in Subjects With Type 2 DiabetesNCT06895018Conditions: Diabetes Mellitus Type 2. Interventions: Supplementation with Polyphenol Rich Drink; Supplementation with Control Drink (Placebo) | Completed | Not applicable | Federico II University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06895018 (opens in a new tab)Primary source | System checked NPHLA updated |
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular DystrophyNCT07642635Conditions: Duchenne Muscular Dystrophy (DMD). Interventions: Semaglutide (Rybelsus®); Placebo | Recruiting | Phase 1 / Phase 2 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07642635 (opens in a new tab)Primary source | System checked NPHLA updated |
| PORTIONS_V_RCT: Comprehensive Intervention for Changing Eating Habits Through Portion ControlNCT07932977Conditions: Lifestyle Intervention; Weight Management; Behaviour Change; Portion Size. Interventions: Portion control; Healthy lifestyle | Recruiting | Not applicable | Clinica Universidad de Navarra, Universidad de Navarra | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07932977 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESIST-EXHALE: Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With ObesityNCT07931235Conditions: Obesity (Disorder). Interventions: Structured resistance training; Tirzepatide | Not yet recruiting | Phase not stated | Technical University of Munich | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931235 (opens in a new tab)Primary source | System checked NPHLA updated |
| SURPASS-EARLY: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 DiabetesNCT05433584Conditions: Type 2 Diabetes. Interventions: Tirzepatide; Antihyperglycemic medication | Active, not recruiting | Phase 4 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05433584 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESIST-EXPLORE: Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in ObesityNCT07931196Conditions: Obesity (BMI Equal to or >30). Interventions: Structured resistance training; Tirzepatide | Not yet recruiting | Phase not stated | Technical University of Munich | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07931196 (opens in a new tab)Primary source | System checked NPHLA updated |
| FIPS: Filler Post Market Survey (FIPS)NCT07475455Conditions: Wrinkle Reduction. Interventions: Hyaluronic acid dermal filler (routine clinical use) | Active, not recruiting | Phase not stated | Croma-Pharma GmbH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07475455 (opens in a new tab)Primary source | System checked NPHLA updated |
| PREPARE CHILD: PRE-Pregnancy Weight Loss And the Reducing Effect on CHILDhood Overweight - AarhusNCT05798494Conditions: Overweight and Obesity; Weight Loss; Pregnancy Related; Child Nutrition Sciences; Body Composition. Interventions: Weight loss intervention | Recruiting | Not applicable | Ulla Kampmann Opstrup | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05798494 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study to Evaluate Xtressé Gummy Supplement in Women With Thinning HairNCT07919782Conditions: Androgenetic Alopecia. Interventions: Xtressé Hair Growth Gummies; Placebo Comparator | Not yet recruiting | Not applicable | Restore Biologics Holdings, Inc. dba Xtressé | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07919782 (opens in a new tab)Primary source | System checked NPHLA updated |
| ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNCT07517042Conditions: Obesity; Weight Control. Interventions: Mazdutide; Intensive Lifestyle Intervention; Mazdutide Placebo; Usual Lifestyle Counseling | Recruiting | Not applicable | Shanghai Zhongshan Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07517042 (opens in a new tab)Primary source | System checked NPHLA updated |
| Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast CancerNCT07880106Changed in the last 7 days Status changed from “Not yet recruiting” to “Recruiting” · Conditions: Lung Cancer Non-small Cell; Colorectal Cancer; Stomach Cancer; Hepatocellular Carcinoma; Breast Cancer | Recruiting | Phase not stated | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07880106 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Conditions: Obesity. Interventions: ALN-2232; Placebo; Tirzepatide | Recruiting | Phase 1 / Phase 2 | Alnylam Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07463846 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentNCT00739362Conditions: Electric Stimulation Therapy; Obesity; Weight Loss; Eating. Interventions: Transcranial Direct Current Stimulation (TDCS); Sham/no-stimulation | Active, not recruiting | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT00739362 (opens in a new tab)Primary source | System checked NPHLA updated |
| SURMOUNT-MMO: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512Conditions: Obesity; Overweight. Interventions: Tirzepatide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05556512 (opens in a new tab)Primary source | System checked NPHLA updated |
| TOPAZ: Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized TrialNCT07734792Changed in the last 7 days Status changed from “Not yet recruiting” to “Recruiting” · Conditions: Acute Ischemic Stroke (AIS). Interventions: Tirzepatide; Standard Medical Care (SMC) | Recruiting | Phase 2 / Phase 3 | yifang zhu | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07734792 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesNCT07112872Changed in the last 7 days Status changed from “Active, not recruiting” to “Recruiting” · Conditions: Type 2 Diabetes Mellitus. Interventions: Tifeglipron; Semaglutide; Placebo | Recruiting | Phase 2 | Hoffmann-La Roche | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07112872 (opens in a new tab)Primary source | System checked NPHLA updated |
| GZBF: Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447Conditions: Obesity. Interventions: Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study. | Recruiting | Phase 2 | Hudson Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07467447 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)NCT03407079Conditions: Healthy Volunteers; Overweight. Interventions: Sucralose; Placebo | Recruiting | Phase 2 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03407079 (opens in a new tab)Primary source | System checked NPHLA updated |
| ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNCT07850063Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Interventions: Survodutide; Placebo matching survodutide | Not yet recruiting | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07850063 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864Conditions: Obesity. Interventions: survodutide; Placebo | Completed | Phase 3 | Boehringer Ingelheim | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06077864 (opens in a new tab)Primary source | System checked NPHLA updated |
| Deep Brain Stimulation Surgery for Focal Hand DystoniaNCT02911103Conditions: Dystonia; Focal Dystonia; Musician's Dystonia. Interventions: DBS surgery; Medtronic Activa Rechargeable System | Active, not recruiting | Phase 1 / Phase 2 | National Institute of Neurological Disorders and Stroke (NINDS) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT02911103 (opens in a new tab)Primary source | System checked NPHLA updated |
| The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced DiabetesNCT06318442Conditions: Steroid-Induced Diabetes; Steroid Induced Hyperglycemia. Interventions: Semaglutide Oral Product; Metformin Oral Tablet; Placebo | Recruiting | Not applicable | Imperial College London | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06318442 (opens in a new tab)Primary source | System checked NPHLA updated |
| Optimum 2: A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusNCT06778967Conditions: Type 2 Diabetes Mellitus (T2DM). Interventions: GZR18; semaglutide | Completed | Phase 3 | Gan & Lee Pharmaceuticals. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06778967 (opens in a new tab)Primary source | System checked NPHLA updated |
| PAOLA: A Study of NT 201 Doses in the Treatment of Platysma ProminenceNCT05773053Conditions: Platysma Prominence. Interventions: NT 201; NT 201 Placebo | Completed | Phase 2 | Merz Aesthetics GmbH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05773053 (opens in a new tab)Primary source | System checked NPHLA updated |
| GZR18-BWM-303: Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossNCT07292441Conditions: Overweight or Obesity. Interventions: GZR18 injection; Placebo | Completed | Phase 3 | Gan & Lee Pharmaceuticals. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07292441 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or ObesityNCT07929298Conditions: Overweight , Obesity; Weight Management. Interventions: ecnoglutide tablet; placebo with matching dosage | Not yet recruiting | Phase 2 | Hangzhou Sciwind Biosciences Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07929298 (opens in a new tab)Primary source | System checked NPHLA updated |
| CLEAR-GLP1: 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 ReceptorNCT07929233Conditions: Retained Gastric Content; Delayed Gastric Emptying; Obesity; Type 2 Diabetes Mellitus (DM). Interventions: 24-Hour Clear Liquid Diet; Standard Fasting | Not yet recruiting | Not applicable | Portuguese Oncology Institute, Coimbra | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07929233 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityNCT07830329Conditions: Hidradenitis Suppurativa. Interventions: Olatorepatide; Placebo | Recruiting | Phase 2 | Regeneron Pharmaceuticals | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07830329 (opens in a new tab)Primary source | System checked NPHLA updated |
| IMPACT: The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional CapacityNCT07929831Conditions: Obesity & Overweight | Recruiting | Phase not stated | Radboud University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07929831 (opens in a new tab)Primary source | System checked NPHLA updated |
| Preoperative Weight Loss for Open Abdominal Wall ReconstructionNCT05925959Conditions: Abdominal Wall Hernia. Interventions: Preoperative Weight Management Program | Recruiting | Not applicable | Benjamin T. Miller | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05925959 (opens in a new tab)Primary source | System checked NPHLA updated |
| GRABS-0: GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialNCT06162715Conditions: Severe Obesity; Obesity; BMI Greater Than 30. Interventions: Tirzepatide; Standard of Care post-gastric bypass | Active, not recruiting | Phase 2 / Phase 3 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06162715 (opens in a new tab)Primary source | System checked NPHLA updated |
| RESIST-MIND: Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight LossNCT07929571Conditions: Obesity (Disorder). Interventions: Structured resistance training; Tirzepatide | Not yet recruiting | Phase not stated | Technical University of Munich | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07929571 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.